Actuate Therapeutics ACTU
NASDAQ ACTU
$0.30 +0.01 (+1.75%)
As of: Nov 11, 2026 · 3:59 PM EST

Actuate Therapeutics (ACTU) Return on Assets [ROA] (2024 - 2026)

Updated

Actuate Therapeutics (ACTU) recorded Return on Assets [ROA] of -216.04% in Q2 2026, up 203.60 percentage points from -419.63% a year earlier.

Analysis

Actuate Therapeutics (ACTU) Return on Assets [ROA] (2024 - 2026) Analysis & Trends

For FY2025, Actuate Therapeutics reported Return on Assets [ROA] of -190.35%, up 214.99 percentage points from FY2024.

  • Across earlier years, Return on Assets [ROA] came in at -405.35% in FY2024.
  • Quarterly Return on Assets [ROA] has ranged from -419.63% in Q2 2025 to -140.02% in Q4 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 19.00%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 8.08%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 7.32%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 1.87%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.36%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 9.80%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -7.67%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 2.00%
10 Actuate Therapeutics 7.20 Mn -35.44 Mn - -289.92%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -289.92%
Mar 31, 2026 -187.71%
Dec 31, 2025 -140.02%
Sep 30, 2025 -195.45%
Jun 30, 2025 -419.65%
Mar 31, 2025 -340.71%
Dec 31, 2024 -211.68%
Sep 30, 2024 -326.03%
API Access

Actuate Therapeutics Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=ACTU&period=max&api_key=YOUR_API_KEY